Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Aurora kinases A and B and familial breast cancer risk.

Literature DB >> 16762494

Aurora kinases A and B and familial breast cancer risk.

Sandrine Tchatchou¹, Michael Wirtenberger, Kari Hemminki, Christian Sutter, Alfons Meindl, Barbara Wappenschmidt, Marion Kiechle, Peter Bugert, Rita K Schmutzler, Claus R Bartram, Barbara Burwinkel.

Abstract

Aurora genes play a crucial role in tumourigenesis and are overexpressed in many kinds of cancers. We investigated whether coding variants within the Aurora genes are associated with familial breast cancer risk. While AURKA Phe31Ile (1712T>A) and AURKB Thr298Met (893G>A) showed no association, the synonymous AURKB Ser295Ser (885A>G) polymorphism resulted in an increased breast cancer risk for carriers of the homozygous 885G genotype (OR=1.45, 95% CI=1.05-2.0, P=0.02). Due to the impact of aurora kinases in the loss of chromosomal integrity during carcinogenesis, this variant may also influence the therapy outcome in breast cancer.

Entities: Disease Gene

Mesh：

Substances：

Year: 2006 PMID： 16762494 DOI： 10.1016/j.canlet.2006.05.002

Source DB: PubMed Journal: Cancer Lett ISSN： 0304-3835 Impact factor: 8.679

Keyword Cloud
Cited

19 in total

1. An integrated pharmacokinetic-pharmacodynamic model for an Aurora kinase inhibitor.

Authors: Hiroko Kamei; Robert C Jackson; Daniella Zheleva; Fordyce A Davidson
Journal: J Pharmacokinet Pharmacodyn Date: 2010-08-08 Impact factor: 2.745

2. Association between the STK15 polymorphisms and risk of cancer: a meta-analysis.

Authors: Jun Qin; Xiao-Feng He; Wu Wei; Zhi-Zhong Liu; Jian-Jun Xie; Wei Wang; Ya-Ping Du; Yu Chen; Hui-Qiang Si
Journal: Mol Genet Genomics Date: 2014-08-26 Impact factor: 3.291

3. Histone modifiers in cancer: friends or foes?

Authors: Idan Cohen; Elżbieta Poręba; Kinga Kamieniarz; Robert Schneider
Journal: Genes Cancer Date: 2011-06

4. Inherited variants in the inner centromere protein (INCENP) gene of the chromosomal passenger complex contribute to the susceptibility of ER-negative breast cancer.

Authors: Maria Kabisch; Justo Lorenzo Bermejo; Thomas Dünnebier; Shibo Ying; Kyriaki Michailidou; Manjeet K Bolla; Qin Wang; Joe Dennis; Mitul Shah; Barbara J Perkins; Kamila Czene; Hatef Darabi; Mikael Eriksson; Stig E Bojesen; Børge G Nordestgaard; Sune F Nielsen; Henrik Flyger; Diether Lambrechts; Patrick Neven; Stephanie Peeters; Caroline Weltens; Fergus J Couch; Janet E Olson; Xianshu Wang; Kristen Purrington; Jenny Chang-Claude; Anja Rudolph; Petra Seibold; Dieter Flesch-Janys; Julian Peto; Isabel dos-Santos-Silva; Nichola Johnson; Olivia Fletcher; Heli Nevanlinna; Taru A Muranen; Kristiina Aittomäki; Carl Blomqvist; Marjanka K Schmidt; Annegien Broeks; Sten Cornelissen; Frans B L Hogervorst; Jingmei Li; Judith S Brand; Keith Humphreys; Pascal Guénel; Thérèse Truong; Florence Menegaux; Marie Sanchez; Barbara Burwinkel; Frederik Marmé; Rongxi Yang; Peter Bugert; Anna González-Neira; Javier Benitez; M Pilar Zamora; Jose I Arias Perez; Angela Cox; Simon S Cross; Malcolm W R Reed; Irene L Andrulis; Julia A Knight; Gord Glendon; Sandrine Tchatchou; Elinor J Sawyer; Ian Tomlinson; Michael J Kerin; Nicola Miller; Christopher A Haiman; Fredrick Schumacher; Brian E Henderson; Loic Le Marchand; Annika Lindblom; Sara Margolin; Maartje J Hooning; Antoinette Hollestelle; Mieke Kriege; Linetta B Koppert; John L Hopper; Melissa C Southey; Helen Tsimiklis; Carmel Apicella; Seth Slettedahl; Amanda E Toland; Celine Vachon; Drakoulis Yannoukakos; Graham G Giles; Roger L Milne; Catriona McLean; Peter A Fasching; Matthias Ruebner; Arif B Ekici; Matthias W Beckmann; Hermann Brenner; Aida K Dieffenbach; Volker Arndt; Christa Stegmaier; Alan Ashworth; Nicholas Orr; Minouk J Schoemaker; Anthony Swerdlow; Montserrat García-Closas; Jonine Figueroa; Stephen J Chanock; Jolanta Lissowska; Mark S Goldberg; France Labrèche; Martine Dumont; Robert Winqvist; Katri Pylkäs; Arja Jukkola-Vuorinen; Mervi Grip; Hiltrud Brauch; Thomas Brüning; Yon-Dschun Ko; Paolo Radice; Paolo Peterlongo; Giulietta Scuvera; Stefano Fortuzzi; Natalia Bogdanova; Thilo Dörk; Arto Mannermaa; Vesa Kataja; Veli-Matti Kosma; Jaana M Hartikainen; Peter Devilee; Robert A E M Tollenaar; Caroline Seynaeve; Christi J Van Asperen; Anna Jakubowska; Jan Lubinski; Katarzyna Jaworska-Bieniek; Katarzyna Durda; Wei Zheng; Martha J Shrubsole; Qiuyin Cai; Diana Torres; Hoda Anton-Culver; Vessela Kristensen; François Bacot; Daniel C Tessier; Daniel Vincent; Craig Luccarini; Caroline Baynes; Shahana Ahmed; Mel Maranian; Jacques Simard; Georgia Chenevix-Trench; Per Hall; Paul D P Pharoah; Alison M Dunning; Douglas F Easton; Ute Hamann
Journal: Carcinogenesis Date: 2015-01-13 Impact factor: 4.944

10. The cell cycle as a therapeutic target against Trypanosoma brucei: Hesperadin inhibits Aurora kinase-1 and blocks mitotic progression in bloodstream forms.

Authors: Neal Jetton; Karen G Rothberg; James G Hubbard; John Wise; Yan Li; Haydn L Ball; Larry Ruben
Journal: Mol Microbiol Date: 2009-03-06 Impact factor: 3.501

Aurora kinases A and B and familial breast cancer risk.

1. An integrated pharmacokinetic-pharmacodynamic model for an Aurora kinase inhibitor.

2. Association between the STK15 polymorphisms and risk of cancer: a meta-analysis.

3. Histone modifiers in cancer: friends or foes?

4. Inherited variants in the inner centromere protein (INCENP) gene of the chromosomal passenger complex contribute to the susceptibility of ER-negative breast cancer.

Review 5. Shared and separate functions of polo-like kinases and aurora kinases in cancer.

6. Genetic variation in cell cycle regulatory gene AURKA and association with intrinsic breast cancer subtype.

7. Partial Correlation Estimation by Joint Sparse Regression Models.

Review 8. Current and future trials of targeted therapies in cutaneous melanoma.

9. Expression of Aurora A (but not Aurora B) is predictive of survival in breast cancer.

10. The cell cycle as a therapeutic target against Trypanosoma brucei: Hesperadin inhibits Aurora kinase-1 and blocks mitotic progression in bloodstream forms.